All Updates

All Updates

icon
Filter
Funding
Mereo BioPharma Group raises USD 50 million in underwritten offering for the pre-launch of setrusumab in Europe
Precision Medicine
Jun 14, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 14, 2024

Mereo BioPharma Group raises USD 50 million in underwritten offering for the pre-launch of setrusumab in Europe

Funding

  • Mereo BioPharma Group has announced an underwritten offering of 12,531,300 of its American Depositary Shares (ADSs) at USD 3.99 per ADS, raising approximately USD 50 million in gross proceeds. Investors in direct offering include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors and existing shareholders like Rubric Capital Management, Rock Springs Capital, and Janus Henderson Investors. The closing of the offering is expected to be on or around June 17, 2024, subject to meeting closing conditions.

  • The proceeds are planned to be used for the setrusumab program and its pre-launch activities in Europe as well as for working capital and other general corporate purposes.

  • UK-based Mereo BioPharma Group is a clinical-stage biopharmaceutical company specializing in developing therapeutics for rare diseases and oncology. The company’s pipeline includes two primary rare disease candidates: setrusumab and alvelestat. Setrusumab is an antibody targeting osteogenesis imperfecta (OI), and alvelestat is an oral small molecule aimed at treating severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The company is also working on oncology candidates such as etigilimab and navicixizumab.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.